In part three of this little series called #MakeItTen, we interviewed Dieter Lingelbach from Sirion Biotech. Sirion is an investment out of our CV II fund. Enjoy reading and as always, fell free to share.
Dieter, please introduce Sirion Biotech in less than 10 words.
SIRION enables drug development to pursue gene therapies and tumor vaccines.
Follow this link to read the complete interview on our Medium blog.